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Abstract
Recent body composition analyses, together with assessments of insulin resistance, aerobic fitness,
and intima-media thickness of the common carotid artery, have shown that metabolically-benign
obese subjects have a similar BMI, waist circumference, and subcutaneous abdominal fat compared
with non-metabolically-benign obese subjects. Research has suggested that 25-30% of the obese
population do not need either treatment or prevention of secondary disorders. Therefore,
assessment of functional body composition should replace nutritional status-based risk assessments
(such as the body mass index) in both metabolic research and clinical decision making. The concept of
‘functional’ body composition gives us a more sophisticated view on nutritional status, metabolism,
endocrinology, and diseases. Knowledge of detailed body composition enables characterization of
biomedical traits which will give functional evidence relating genetic variants.
Introduction and context
The current practices to assess nutritional status include
the calculation of body mass index (BMI) by dividing
weight (kg) by the square of the height (m). Normative
data are most frequently used to identify over- and
underweight subjects. In the overweight, waist circum-
ference is measured for additional assessment of health
risks. Recent methodological and technological advances
[for example, using magnetic resonance imaging (MRI)
and dual energy X-ray absorptiometry (DXA) technolo-
gies] have enabled accurate and detailed body composi-
tion analysis (BCA) and assisted in the development of
advances in body composition, endocrine, and meta-
bolic research. BCA is now standard in investigations on
energy and macronutrient metabolism. The introduction
of valid field methods such as bioelectrical impedance
analysis (BIA) has led to broader applications of BCA
within epidemiological and clinical studies. The present
commentary aims to discuss the utility of body
composition data in the assessment of metabolic,
endocrine, and physical function. This article will have
a major focus on the regulation of energy expenditure
and energy balance.
Assessment of body components and modeling of body
composition at molecular, cellular, and tissue levels
results in the identification of different characteristics
of the body [for example, tissue hydration, electrical
resistance, mineral content, kilograms of fat, and fat-free
mass (FFM)] [1]. Within epidemiology, these data can
be used to generate population-specific reference values
and suitable cut-offs (for example, by using percentiles
to characterize over- and underweight subjects) [2,3].
BCA data (such as body fat distribution) may also be
included in scores used for assessment of cardiometa-
bolic risk [4,5]. Characterising individual body compo-
nents also helps to identify specific types of
malnutrition via the assessment of body fat and muscle
mass (for example, identification of sarcopenia with
reduced skeletal muscle mass at normal or increased fat
mass in patients with rheumatoid arthritis [6]). BCA
data are also associated with clinical prognosis, for
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shown to predict survival in severely ill patients [7].
Assessment of body components and how they change
with regard to nutrition, development, inflammation,
and/or wasting disease is mandatory for understanding
metabolism, for example, how it changes in response to
starvation [8], health (for example, muscle mass is one
determinant of bone health [9]), and clinical outcome
(in the case of wasting diseases [7]).
Major recent advances
Impact of fat mass on energy balance
FFM is the major determinant of energy expenditure
and can account for about 60-80% of the variance in
energy expenditure [10]. Recent work also shows that
the higher the amount of FFM, the higher the resting
energy expenditure (REE). FFM is heterogeneous and
the proportion of muscle and organ mass contributes
to the variance in REE [11]. On the other side of the
e n e r g yb a l a n c ee q u a t i o n ,t h e r ei sac l o s ea n de x p o -
nential association between fat mass (FM) and plasma
leptin concentrations, which are considered to be a
major signal in regulating appetite and thus energy
intake [12]. Higher FM tends to correlate with higher
plasma leptin levels. Reducing FM increases energy
intake by lowering leptin secretion rates, whereas
decreasing FFM lowers REE. The reverse of the previous
sentence is also true; increases in FM are associated
with high plasma leptin levels and increases in FFM
with high REE.
Evidence that fat mass affects energy metabolism
Overweight and obese subjects have a higher REE
than their lean controls, mainly explained by their
higher FFM. However, REE differences between lean
and obese subjects remained after adjustments for FFM
and age [13]. In addition, most of the between-group
differences in REE disappeared after further adjustment
for FM. Based on multiple regression analyses, energy
expenditure of FFM was found to be three to seven
times greater than energy expenditure of FM [14].
A recent study used regression analyses to show that
the relative contribution of FM on the variance in REE
increased from low to normal with increasing grades
of adiposity (that is, up to a FM of 40% body weight)
but sharply decreased at very high (>40% FM) and
extreme (>50% FM) grades of obesity [15]. The latter
f i n d i n gm i g h ts u g g e s tat h r e s h o l de f f e c to fF Mt h a t
cannot be explained on the basis of present knowledge,
however, it may suggest that the metabolic rate of FM
is reduced in very obese subjects, that is, FM itself has
a ‘thermic effect’ on metabolic rate that varies with
its mass.
Explaining how fat mass regulates REE
Fat cells normally have a low metabolic rate (19 kJ or
about 5 kcal/kg ¥ d [14,16]), but another recent study
suggests that the mass-dependent effect of FM may be
explained, not by fat cell metabolism itself, but by the
secretory activity of fat cells (for example, secretion
of adipocytokines and/or hormones). It can also be
explained by metabolic, inflammatory, and haemody-
namic disturbances associated with being overweight
[16]. A high FM and abdominal obesity are frequently
associated with metabolic disturbances (such as insulin
resistance and increased sympathetic nervous system
activity) and co-morbidity (for example, different traits
of the metabolic syndrome), which add to the variance
in REE. Also, insulin resistance and elevated blood
pressure are associated with higher REE, even after
adjustments for FFM, FM, and age [17].
Data on patients with partial lipodystrophy syndromes
(characterized by a loss of subcutaneous fat, low plasma
levels of adipocytokines, and a greater percentage of
trunk fat, as well as the presence of ectopic fat in non-
adipose tissue such as skeletal muscle and the liver)
provide further information on the role of FM in
regulating REE. In patients with congenital lipodystro-
phies, REE is 20-70% higher than normal levels [18]. REE
per kg of FFM was also higher in patients with HIV
lipodystrophy compared with HIV-infected patients
without lipodystrophy [19]. A recent study proposes
that this increase in REE is acompensatory mechanism to
dissipate calories which cannot be stored normally [19].
These data suggest that REE can be affected in different
and indirect ways depending on the location of the fat
depots (that is, subcutaneous, visceral, or ectopic fat),
and the storage capacity of the adipocytes.
A recent study showed that, in adults, the number of
fat cells stays constant and about 10% of fat cells are
renewed annually [20]. The mean size of adipocytes
increases with FM up to a point and then decreases.
Adipocyte cellularity and triglyceride accumulation
within lipid droplets is associated with morbidity.
However, the association between adipocyte size and
FM differs with region. Enlarged abdominal adipocytes
are associated with visceral and subcutaneous abdom-
inal fat, whereas femoral adipocyte size is related to
percentage body fat, and gluteal adipocyte size is related
to visceral fat [21]. Enlarged subcutaneous fat cells are
associated with insulin resistance, independent of FM
[22]. Therefore, large fat cells may also result in a
relatively higher REE. There is now evidence from
experimental data that lipid droplet structure (large
unilocular versus smaller multilocular droplets) is
associated with mitochondrial oxidative metabolism,
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and energy expenditure [23]. Thus, the effect of FM on
REE varies with fat depots, fat cell size, and lipid droplet
structure.
Is there a feedback between fat mass and
energy metabolism?
The feedback mechanism of FM on energy metabolism
is not known, but leptin has been considered as a
candidate for such a signal from fat [24]. Animal data
have suggested a ‘thermic’ effect of leptin, and leptin
has been shown to directly stimulate thermogenesis in
mouse skeletal muscle [25]. It has been proposed that
leptin may uncouple proteins [26] and increase substrate
cycling between de novo lipogenesis and mitochondrial
lipid oxidation [25], and recent work suggests that this
is diminishing phosphatidylinositol-3 kinase and AMP-
activated protein kinase signaling [27]. When compared
with animal data, a ‘thermic’ effect of leptin is equivocal
in humans. Recent observational studies do not suggest
that leptin has a ‘thermic’ effect in normal weight or
obese subjects [28]. Using leptin to treat a child that had
congenital leptin deficiency [29] and obese patients that
had increased plasma leptin concentrations [30] resulted
in substantial weight loss but did not affect REE, and REE
adjusted for FFM was reduced rather than increased. In
obese subjects, leptin administration does not seem to
accelerate weight loss as a supplement to diet interven-
tion unless it is given in supraphysiological doses [31].
A recent study showed that, in addition, substituting
leptin for the physiological decrease in plasma leptin
concentrations in weight-reduced (having undergone a
10% reduction in body-weight), normal-weight, or
overweight healthy subjects had no effect on REE or
REE adjusted for FFM [32]. These data argue against a
‘thermic’ effect of leptin in humans. However, contrary to
dose-response characteristics of many hormones, leptin
may not have effects at high plasma concentrations; its
‘thermic’ effect may become obvious below a certain
threshold level only. In fact, new data in patients with
anorexia nervosa suggest a steep association between
plasma leptin levels and REE in underweight patients,
which disappears after weight gain (V Haas, K Gaskin, MJ
Müller, unpublished data). It is unclear whether the
threshold may be changed (for example, in obese
subjects with chronically elevated leptin levels).
Metabolic adaptations during weight changes and disease
A broader concept of functional body composition
includes both mass-dependent and mass-independent
alterations in body function. The latter reflects metabolic
‘elasticity’ and includes mass-independent changes in
metabolism in response to different stimuli such as
fasting, feeding, work load, short sleep, disease, or stress.
Inter-individual variance in metabolic ‘elasticity’ con-
tributes to energy balance. Detailed body composition
analyses may provide a clue to explain metabolic
‘elasticities’. A recent study comparing obese subjects
who had large decreases in REE in reponse to caloric
restriction with those who had only small diet-induced
adaptations revealed that the former patients were
‘thrifty’ (that is, weight loss in response to hypocaloric
nutrition was 8 kg compared with 10 kg in the non-
thrifty group) and they could conserve fat-free, liver, and
kidney mass at a concomitant greater fall in plasma
triiodothyronine (T3) concentration [33]. The ‘thrifty’
phenotype could not be identified by any ap r i o r i
measure of body composition, fat distribution (includ-
ing liver fat), metabolism, or plasma hormone concen-
trations. These data suggest that adaptive thermogenesis
is related to conservation of FFM and its composition, as
well as to T3 production. Thus, for a clinician, data on
body composition and metabolism should be seen in
the broader context of plasma thyroid hormone con-
centrations and/or biomarkers of stress in order to
characterize the metabolic phenotype.
Future directions
Genetic basis of energy metabolism
Body composition and metabolism have underlying
genetic components. In family studies, heritability esti-
mates of individual body components are variable, for
example, 0.05 for BMI compared with 0.25 for percent
body fat (and may exceed 0.50 when individual variables
are taken into account) [34,35]. After adjusting REE for
FFM, FM, age, and sex, a considerable variance of about
150 kcal/d remained [36,37] that has not yet been
explained.AdjustedREEwasmoderatelyheritable(around
0.30 [16,35-37]) but presently there is no clear evidence
that specific genes add to the interindividual variance in
REE [38,39]. In future, research into traits defined by
measures of functional body composition (for example,
changes in REE-FFM with under- and overfeeding) will
provide functional evidence relating genetic variants.
Use of cut-offs in body composition research
The definitions of both ‘overweight’ and ‘malnutrition’
should be reconsidered now that we are faced with the
concept of functional body composition. Suitable cut-
offs of body weight and/or body components (such as
those based on percentiles or health outcomes) do not
take into account functional aspects. In future, it is likely
that the terms ‘overweight’ and ‘malnutrition’ will be
defined more in terms of function in the context of body
composition (for example, by their affect on metabolism
and inflammation) rather than mere nutritional status.
Current guidelines recommend weight-loss therapy for
patients with a BMI ≥30 kg/m² and for patients with a
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circumference amongst other risk factors. However, there
is substantial heterogeneity within obese subjects as to
their overweight-associated health risks [40,41], suggest-
ing the need for detailed assessment of body composi-
tion together with energy, glucose, and lipid metabolism
(thatis,anassessmentof‘functional’bodycomposition).
Are there healthy obese subjects and can they be identified
by assessment of detailed body composition?
Based on cross-sectional data on 5,440 adult participants
of the NHANES (National Health and Nutrition Exam-
ination Survey) 1999-2004, 51.3% of overweight and
31.7% of obese adults were metabolically healthy as
defined via the absence of cardiometabolic abnormal-
ities including elevated blood pressure, hyperlipidemia,
insulin resistance, and elevated serum levels of C-reactive
protein [40]. Correlates of no- or low-risk in overweight
and obese subjects were young age,ethnicity, high leisure
time, physical activity, and a small waist circumference.
In another clinical study, 25.4% of obese subjects were
characterized as metabolically benign [41]. Body com-
position analyses (including measurements of ectopic fat
in the liver and muscle by MR-spectroscopy) together
with assessments of insulin resistance, aerobic fitness,
and intima-media thickness of the common carotid
artery, showed that metabolically-benign compared with
non-metabolically-benign obese subjects had a similar
BMI, waist circumference, and subcutaneous abdominal
fat, but had slightly lower visceral fat mass and higher
ectopic fat deposits in muscle and particularly in the liver
[40]. These data suggest that 25-30% of the obese
population do not need either treatment or prevention
of secondary disorders. Clearly, detailed body composi-
tion measurements have to be combined with a measure
of ectopic fat and/or insulin resistance in order to explain
the meaning of nutritional status.
To summarize, assessment of functional body composi-
tion should replace nutritional status-based risk assess-
ments and needs to be included in metabolic research
and clinical decision making.
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